Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 6/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847850 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL5847985 | 0.92 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL5847977 | 0.92 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNA3 | |
| SCHEMBL5848246 | 0.90 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL5848254 | 0.90 | CHRNB2 (0.48) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL5848274 | 0.81 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL5849355 | 0.81 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL5848270 | 0.81 | CHRNB2 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL5848281 | 0.75 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL5848286 | 0.75 | CHRNB2 (0.34) | CHRNB2CHRNA4CHRNA3CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022706-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-04-04 | — | — | US | claimed |
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CLARK THOMAS JEFFREY (US) | 2004-08-05 | — | — | US | claimed |
| US-6624167-B1 | Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can | TARGACEPT, INC. | 2003-09-23 | — | — | US | claimed |
| EP-1305316-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | Targacept, Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| WO-2002012245-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | TARGACEPT, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-7022706-B2 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CLARK THOMAS JEFFREY (US) | 2004-08-05 | — | — | US | disclosed |
| US-6624167-B1 | Compounds that are capable of affecting nicotinic cholinergic receptors. A wide variety of conditions and disorders, and particularly conditions and disorders associated with dysfunction of the central and autonomic nervous systems can | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| EP-1305316-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | Targacept, Inc. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002012245-A2 | AZABICYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | TARGACEPT, INC. (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152723-A1 | Pharmaceutical compositions and methods for use | CHRNA7, CHRNA10, CHRNG | CHRNB2 9/4885CHRNA4 17/4885CHRNA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.